建平阳昆化合物通过TLR4/MyD88/NF-κB信号通路缓解亚托邦性皮炎

Xuesong Yang1, Zhimin Wang1, Hong Huang1

  • 1Department of Dermatology, First Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming 650032, Yunnan, China.

Heliyon
|January 1, 2024
PubMed
概括

济安皮阳曲化合物 (JPYXQFC) 通过抑制TLR4/MyD88/NF-κB通路,有效治疗亚托皮炎 (AD). 这种中国药物在细胞模型和AD诱导的老鼠中减少了炎症和过敏反应.